For the Inventor, By the Inventor

Enter assignee name

Marlborough, MA, United States of America

Phio Pharmaceuticals Corp.

USPTO Granted Patents = 23

% Expired Patents = 21.7

EPO Patents = 10

Trademarks = 1

Forward Citations = 197

Loading Chart...

Loading Chart...

23 inventors (with patents filed for the assignee):

William Salomon (14 out of 28 patents)

Joanne Kamens (14 out of 30 patents)

Tod M Woolf (14 out of 50 patents)

4. Anastasia Khvorova (14 out of 206 patents)

5. James Cardia (12 out of 22 patents)

6. Dmitry Samarsky (10 out of 22 patents)

7. Pamela A Pavco (7 out of 13 patents)

8. Karen G Bulock (5 out of 8 patents)

9. Lyn Libertine (5 out of 8 patents)

10. Michael Francis Byrne (3 out of 14 patents)

11. Gerard Cauwenbergh (2 out of 2 patents)

12. Michelle Miller (1 out of 2 patents)

13. Joke Hedwig Vandesompele (1 out of 1 patent)

14. Gert Van Peer (1 out of 1 patent)

15. Alexey Wolfson (1 out of 2 patents)

23 patents: Sort by Forward Citations

1. 12544344 - TOPICAL DELIVERY OF NUCLEIC ACID COMPOUNDS (2026-02-10),

2. 11926828 - Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1 (2024-03-12),

3. 11667915 - RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality (2023-06-06),

4. 11584933 - RNA interference in ocular indications (2023-02-21),

5. 11396654 - Neutral nanotransporters (2022-07-26),

6. 11279934 - Methods for treating cancer using nucleic acids targeting MDM2 or MYCN (2022-03-22),

7. 11254940 - Inhibition of MAP4K4 through RNAi (2022-02-22),

8. 11118178 - Reduced size self-delivering RNAI compounds (2021-09-14),

9. 11021707 - Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA (2021-06-01),

10. 11001845 - Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) (2021-05-11),

11. 10934550 - Immunotherapy of cancer (2021-03-02),

12. 10913948 - RNA interference in dermal and fibrotic indications (2021-02-09),

13. 10900039 - Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 (2021-01-26),

14. 10876119 - Reduced size self-delivering RNAI compounds (2020-12-29),

15. 10815485 - RNA interference in skin indications (2020-10-27),

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company specializing in the development of RNA interference (RNAi) therapeutics for the treatment of cancer and other diseases. With a focus on overcoming limitations of existing RNAi technologies, Phio Pharma aims to deliver innovative solutions utilizing its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform. The company's sd-rxRNA molecules have the potential to selectively silence disease-causing genes, providing a targeted approach to therapeutic intervention. Phio Pharma is dedicated to improving patients' lives by advancing the field of RNAi therapeutics through rigorous research, development, and collaboration with industry partners.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Phio Pharmaceuticals Corp.

23 Patents

#21 in Marlborough, MA

#862 in Massachusetts

#14,394 in US

#27,598 in the World

Marlborough, MA, United States of America

Phio Pharmaceuticals Corp.

Forward Citations = 197

23 inventors:

William Salomon (14 out of 28 patents)

Joanne Kamens (14 out of 30 patents)

Tod M Woolf (14 out of 50 patents)

4. Anastasia Khvorova (14 out of 206 patents)

5. James Cardia (12 out of 22 patents)

Please report any incorrect information to [email protected]

Loading…